Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 7/20 | 0.42 |
| ▸ | CETP | P11597 | 3/20 | 0.39 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.38 |
| ▸ | AR | P10275 | 2/20 | 0.37 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.36 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.36 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.36 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.36 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.36 |
| ▸ | UBE2M | P61081 | 1/20 | 0.36 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.36 |
| ▸ | PTGES | O14684 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1893337 | 0.82 | TACR1 (0.44) | TACR1CETPSERPINE1TRPM8 | |
| SCHEMBL3553343 | 0.81 | TACR1 (0.43) | TACR1CETPSERPINE1TRPM8 | |
| SCHEMBL5148340 | 0.79 | TACR1 (0.41) | TACR1CETPSERPINE1 | |
| SCHEMBL1896131 | 0.75 | TACR1 (0.39) | TACR1CETPSERPINE1TRPM8 | |
| SCHEMBL3551821 | 0.74 | CETP (0.61) | CETP | |
| SCHEMBL3729587 | 0.74 | TACR1 (0.43) | TACR1CETP | |
| SCHEMBL3729637 | 0.73 | CETP (0.62) | CETP | |
| SCHEMBL4183431 | 0.73 | CETP (0.67) | CETP | |
| SCHEMBL2759109 | 0.71 | AR (0.48) | TAS2R14AR | |
| SCHEMBL5147175 | 0.71 | TACR1 (0.46) | TACR1SERPINE1UBE2MDCUN1D1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8193365-B2 | CETP inhibitors | MERCK SHARP & DOHME CORP. (US) | 2012-06-05 | — | — | US | disclosed |
| US-20100249024-A1 | CETP INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2010-09-30 | — | — | US | disclosed |
| US-7737295-B2 | CETP inhibitors | MERCK SHARP & DOHME CORP. (US) | 2010-06-15 | — | — | US | disclosed |
| US-20070225365-A1 | Cetp Inhibitors | MERCK & CO., INC. (US) | 2007-09-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225365-A1 | Cetp Inhibitors | CETP, APOB, NPC1 | TACR1 3645/4885CETP 1/4885TAS2R14 4220/4885 |
| US-20100249024-A1 | CETP INHIBITORS | CETP, APOB, NPC1 | TACR1 3645/4885CETP 1/4885TAS2R14 4220/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.